Drugmaker seeks Supreme Court intervention on abortion pill access. Danco Laboratories filed an emergency request to overturn a Fifth Circuit Court decision that blocked mail delivery of mifepristone, the most widely used abortion medication in the United States. The lower court ruling requires patients to obtain the drug at clinics rather than through mail or pharmacies, creating significant disruption for healthcare providers and patients facing time-sensitive medical decisions. The drugmaker argues the restriction causes irreparable harm to the medical system and patients nationwide. Mifepristone has been approved since 2000 and is also used to manage miscarriages. The case highlights ongoing legal battles over abortion access following the 2022 Supreme Court decision that eliminated federal abortion protections, leaving regulation to individual states.
Post from MarketNews_en
Log in to interact with content.